Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King

Executive Summary

Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes
Advertisement

Related Content

GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
American College Of Cardiology Scientific Sessions, In Brief
American College Of Cardiology Scientific Sessions, In Brief
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy
GSK Plays Up Avandia As Diabetes “Engine” After DPP-4 Program Stalls
Novartis Navigates Metabolic Syndrome, Finds Link To Liver Disease
Novartis Navigates Metabolic Syndrome, Finds Link To Liver Disease
Advertisement
UsernamePublicRestriction

Register

PS047621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel